Veteran finance leader Donald Kalkofen joins Genvor (GNVR) as new CFO
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Genvor Incorporated appointed Donald Kalkofen as Chief Financial Officer effective May 18, 2026, initially via a services agreement with Wave Financial Consulting LLC that was amended and restated on May 21, 2026.
Mr. Kalkofen is an experienced biotech CFO with more than 20 years of finance leadership and public company and IPO experience. His amended agreement provides $6,250 in monthly cash compensation and $7,750 in deferred monthly cash compensation through 2026, with cash compensation increasing to $14,000 per month starting January 1, 2027. He is eligible for ten-year options to purchase up to 575,000 shares of common stock, subject to Board approval of an equity plan, shareholder approval, and the effectiveness of a Form S-8 registration statement before the options become exercisable.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 8.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Monthly cash compensation: $6,250 per month
Monthly deferred compensation: $7,750 per month
Future monthly cash rate: $14,000 per month
+5 more
8 metrics
Monthly cash compensation
$6,250 per month
Base cash pay under CFO services agreement from May 18, 2026
Monthly deferred compensation
$7,750 per month
Deferred pay under services agreement through 2026
Future monthly cash rate
$14,000 per month
Cash compensation starting January 1, 2027 for remainder of term
Stock options granted
575,000 options
Ten-year options to purchase common stock under equity plan
Time-based vesting tranche
425,000 options
Vest in equal monthly installments over 12 months from May 18, 2026
Listing-based vesting tranche
150,000 options
Vest on successful listing on a U.S. national securities exchange
Interest on unpaid amounts
6% per annum
Interest rate on amounts not paid when due, compounding monthly
Deferred comp outside limit
24 months
Maximum delay from May 21, 2026 if payment risks going concern
Key Terms
Amended and Restated Acting Chief Financial Officer Services Agreement, going concern, Registration Statement on Form S-8, equity compensation plan, +2 more
6 terms
Amended and Restated Acting Chief Financial Officer Services Agreement financial
"the Company entered into an amendment and restatement of the Kalkofen Service Agreement (the “Amended and Restated Kalkofen Service Agreement”)"
going concern financial
"if the Board determines in good faith that payment on such date would jeopardize the Company's ability to continue as a going concern"
A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.
Registration Statement on Form S-8 regulatory
"the Company becomes eligible to file a Registration Statement on Form S-8 (or any successor form) with the SEC"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
equity compensation plan financial
"the Board shall approve an equity compensation plan (the "Plan") no later than 30 days following the Restatement Date"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
forward-looking statements regulatory
"Statements in this press release about future expectations, plans, and prospects... may constitute "forward-looking statements.""
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
proprietary peptide platform technical
"Genvor is at an exciting inflection point with a proprietary peptide platform, an expanding pipeline"
FAQ
What did Genvor (GNVR) announce in this 8-K filing?
Genvor announced the appointment of Donald Kalkofen as Chief Financial Officer. The company detailed his background, compensation, stock option terms, and the requirement for an equity plan and Form S-8 registration before the options become exercisable.
Who is Donald Kalkofen, the new CFO of Genvor (GNVR)?
Donald Kalkofen is a seasoned finance executive with over 20 years of CFO experience. He previously served as CFO at Alpha Cognition and Protagonist Therapeutics and held senior finance roles at Symantec and West Coast Bancorp, focusing on public-company finance and capital markets.
What is the compensation structure for Genvor’s new CFO?
Under his amended services agreement, Genvor will pay Mr. Kalkofen $6,250 in monthly cash and $7,750 in deferred monthly cash through 2026. Beginning January 1, 2027, his monthly cash compensation during the term increases to $14,000, with unpaid amounts accruing interest at 6% annually.
How many stock options will Genvor’s CFO be eligible to receive?
The agreement provides for ten-year options to purchase up to 575,000 shares of Genvor common stock. These options are to be granted under a new equity compensation plan, with vesting and exercisability conditioned on plan approval and an effective Form S-8 registration statement.
What conditions affect the exercisability of Genvor CFO stock options?
The options will be granted under a Board-approved equity plan that must also receive shareholder approval. They are not exercisable until Genvor files a Form S-8 registration statement covering the option shares and that registration statement becomes effective, after which normal option terms apply.
When is deferred compensation to Genvor’s CFO expected to be paid?
The aggregate deferred compensation is scheduled to be paid in a lump sum by December 31, 2026. If the Board believes payment then would jeopardize Genvor’s ability to continue as a going concern, payment may be delayed, but not beyond 24 months from May 21, 2026.